Search This Blog

Tuesday, August 11, 2026

Iran shifting to offensive doctrine, IRGC commander’s adviser says

 

Iran is shifting from a defensive military doctrine toward an offensive one, with its forces being prepared to conduct operations beyond the country’s borders, Mohammad Reza Naghdi, an adviser to the commander of the Islamic Revolutionary Guard Corps said on Tuesday.

“Whenever conditions require and an order is issued, we must have the capability to take operations to the enemy’s territory and conduct operations away from our own territory,” Naghdi said in an interview with state television.

Naghdi described Iran’s recent war with the United States and Israel as a “real exercise” that allowed its forces to assess their adversaries’ military capabilities in actual combat.

“The latest directives to Iranian commanders emphasized hybrid warfare, which is a mix of coordinated use of military, diplomatic, economic, social and media capabilities,” he added.

“Our production of ballistic missiles exceeds the number being launched. In other words, we are producing more missiles and making them available to our forces than are being fired on the battlefield. We also have a production capacity for drones that exceeds their rate of use and launch, and we have significant production capacity,” Naghdi said.

“Production of this equipment will continue, and even if the war lasts for several years, ballistic missiles will still be produced and fired at the enemy on the final day of the war,” he added.

https://www.iranintl.com/en/202608118694

Houthis say they attacked Saudi military cargo ship in Bab el-Mandeb

 

Yemen’s Iran-aligned Houthis said they attacked a Saudi ship carrying military equipment in the Bab el-Mandeb Strait, according to the Houthi-run Saba news agency. Saudi Arabia has not immediately confirmed the attack. pic.twitter.com/VHhDbwWbNX

https://www.iranintl.com/en/202608119591

Pezeshkian meets Pakistani mediator in Tehran amid push for US-Iran deal

 

Iranian President Masoud Pezeshkian met Pakistani Interior Minister Mohsin Naqvi in Tehran on Tuesday as Islamabad pressed ahead with its mediation between Iran and the United States amid signs of progress toward an agreement.

Pezeshkian told Naqvi that Iran sought to deepen relations with Pakistan “in all fields,” saying closer cooperation could advance mutual interests and strengthen regional stability and security.

Naqvi also met Foreign Minister Abbas Araghchi, as well as Iranian Interior Minister Eskandar Momeni and Oil Minister Mohsen Paknejad, during his visit to Tehran.

Pakistan, alongside Qatar, has been mediating between Tehran and Washington, which are exchanging messages through intermediaries rather than negotiating directly. Pakistani officials said Tuesday that the two sides were close to “some sort” of agreement.

https://www.iranintl.com/en/202608113315

Iraqi PM orders draft law to restrict weapons to state

 

Iraqi Prime Minister Ali Faleh al-Zaidi ordered the preparation of a draft law Tuesday to restrict weapons to the state, the Iraqi News Agency reported, one day after Iran's IRGC Quds Force chief met Tehran-backed militia leaders in Baghdad.

Zaidi said “the most serious threat to the state is the proliferation of weapons,” adding that it “undermines the rule of law and weakens the authority of security institutions.”

In his Monday trip, IRGC Quds Force commander Esmail Qaani met leaders of Iraq’s Popular Mobilization Forces, armed factions and the Coordination Framework in Baghdad and discussed weapons restrictions, Al Hadath reported, citing sources.

https://www.iranintl.com/en/202608119032

Medicaid to stop funding child sex-change hormones, surgeries, protect kids from ‘experimental’ ops

 American taxpayers will no longer be on the hook for child sex-change hormones or surgeries, as a key Trump administration agency announced Tuesday that Medicaid will stop funding such procedures and therapies.

Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz tells Fox News Digital that the decision to implement a rule pulling the funding is “consistent with [the Trump administration’s] commitment to protect children from experimental and life-altering sex-rejecting procedures that carry serious long-term health risks and lack sufficiently reliable evidence of clinical benefit.”

CMS, an agency within the Department of Health and Human Services (HHS), says taxpayer-funded Children’s Health Insurance Program (CHIP) will also cease coverage of sex-change hormones and surgeries.

The rule will not affect mental health treatments for gender dysmorphia and other conditions, which will continue to be covered under Medicaid and CHIP.

The move comes after years of what conservatives called ‘woke’ policies that opened avenues for federal funding of therapies and procedures to allow children to physically — and oftentimes permanently — transition from their biological sex before they could legally drive, get a tattoo or enlist in the US Military.

“Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits,” Oz said. “By cutting off federal funds for these sex-rejecting procedures, we’re following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm so they can truly flourish.”

Dr. Mehmet Oz speaks at a podium with two microphones, gesturing with his left hand, against a blue background with "TING TAXPAYER DOL" visible at the top.
Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz announced that Medicaid will no longer be used to fund child sex-change hormones or surgeries.via REUTERS

Specifically, the “sex-rejecting” treatments that will no longer be covered include cross-sex hormones, puberty blockers and sex-change surgical operations.

CMS and HHS say such procedures “can result in irreversible damage, including infertility, impaired sexual function, diminished bone density, altered brain development, and other lasting physiological effects.”

HHS, under Secretary Robert F. Kennedy Jr., reviewed national and international research on sex-change procedures in minors, which ultimately informed CMS’ decision to reverse federal taxpayer-funded procedures.

“Today, we are ending federal taxpayer funding for sex-rejecting procedures on children,” Secretary Kennedy said in a statement to Fox News Digital. “These interventions carry serious risks and can cause irreversible harm. The federal government will no longer use Medicaid and CHIP dollars to fund procedures that fail to meet the evidentiary standard our children deserve.”

That research “identified significant evidence gaps” and “documented serious safety concerns,” eventually leading to the conclusion that taxpayer funding for such procedures could not be justified comparative to the risks.

Specifically, CMS pointed to the United Kingdom’s Cass Review as one of the cornerstone pieces of research informing the decision.

U.S. Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. and Center for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz shake hands during a press conference.
HHS Secretary Robert F. Kennedy Jr. said the CMS’ decision was based on international and national research on the effect sex-change procedures on children.REUTERS

That review, conducted by Dr. Hilary Cass, concluded in 2024 that research on medical interventions like cross-sex hormones and puberty blockers was limited and not definitive. The report also said that medical interventions had developed significantly faster than evidence proving those interventions were safe.

“The Trump Administration is drawing a clear line: America’s children will not be subjected to life-altering interventions on the taxpayer’s dime without reliable evidence of safety and clinical benefit,” HHS Press Secretary Emily Hilliard told Fox News Digital

“Under the leadership of Secretary Kennedy, federal health care dollars will support evidence-based care that protects children and puts their long-term health first,” she added. “American taxpayers should never be forced to finance interventions when the evidence of benefit is insufficient and the potential consequences for children can be serious and irreversible.”

What follows is a tapering-off period where the Medicaid and CHIP funding will slowly phase out and allow children who are currently getting hormone treatments to receive funding for six months from the date the new rule takes effect.

https://nypost.com/2026/08/11/us-news/medicaid-to-stop-funding-child-sex-change-hormones-and-surgeries/

Autolus ups guidance after rapid commercial ramp

 

Autolus raises 2026 AUCATZYL revenue guidance to $140–$150M as Q2 sales and gross margin inflect sharply

  • Autolus beat fiscal Q2 2026 estimates with non-GAAP EPS $-0.15.
  • AUCATZYL Q2 revenue reached $45.7m, up from $20.9m last year and $26.2m Q1.
  • 2026 AUCATZYL net product revenue guidance raised from $120–135m to $140–150m.
  • Gross margin improved to 55% from 6% in Q1 and negative in 2025.
  • Management targets 65–70% gross margin for adult ALL within 12–18 months.
  • Over 80 U.S. centers now activated; aiming for 90+ U.S. and ~20 U.K. by year-end.
  • Company remains loss-making, with Q2 net loss of $39.1m, though losses narrowed YoY.
  • New Perceptive Advisors credit facility (up to $250m) extends cash runway into Q2 2028.
  • Guidance embeds prudence and potential seasonality; implies flattish-to-slightly-below Q2 revenue run-rate.
  • U.K. launch off to positive start but currently contributes substantially less than 10% of U.S. sales.
  • Multiple 2027–2028 data catalysts in pediatric ALL, lupus nephritis, systemic lupus, and progressive MS.
  • Main concern: achieving sustainable profitability while still dependent on a single commercial asset as pipeline matures.
  • Strong quarter, driven by rapid AUCATZYL commercial ramp and substantial gross margin improvement.

Prelude Therapeutics beats, says $155M cash funds operations into Q2 2028

 

Prelude Therapeutics beats Q2 2026 estimates with EPS -$0.14 and revenue $5.7M, says $155M cash funds operations into Q2 2028

  • Non-GAAP EPS of -$0.14 in fiscal Q2 2026 improved 66% year over year.